Differences in responsiveness of intratympanic steroid injection for intractable vertigo in Meniere's disease

The efficacy of intratympanic steroid (ITS) injection for intractable Meniere's disease has been reported; however, its differences in responsiveness are not fully understood. This study investigated the clinical characteristics of patients who responded to ITS injection treatment. This retrosp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of otolaryngology 2021-11, Vol.42 (6), p.103141-103141, Article 103141
Hauptverfasser: Okuda, Hiroshi, Aoki, Mitsuhiro, Ogawa, Bakushi, Shibata, Hirofumi, Ueda, Natsuko, Ohashi, Toshimitsu, Hayashi, Hisamitsu, Nishihori, Takezumi, Kuze, Bunya, Ogawa, Takenori
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The efficacy of intratympanic steroid (ITS) injection for intractable Meniere's disease has been reported; however, its differences in responsiveness are not fully understood. This study investigated the clinical characteristics of patients who responded to ITS injection treatment. This retrospective study included 32 patients with Meniere's disease who were unable to control frequent vertigo attacks despite conservative treatment for at least 3 months. They received an intratympanic injection of dexamethasone (3.3 mg/mL) in the affected side at least three times. We measured hearing threshold, subjective symptom scores, cervical and ocular vestibular evoked myogenic potential (cVEMP and oVEMP), and performed glycerol and bithermal caloric tests. Satisfactory control of vertigo for 1 year after the first round of injection was found in 18 patients (56.3%; the response group). However, the injections failed to control vertigo in the other 14 patients (43.8%; the non-response group), and they were then treated with middle ear micropressure therapy. The response group showed improvement in low-frequency hearing, whereas hearing acuity did not change in the non-response group. Significantly reduced amplitude of cVEMP on the affected side was found in 62.5% of patients in the response group; however, no patients in the non-response group showed reduced amplitude of cVEMP. ITS injection significantly improved the subjective symptoms for intractable Meniere's disease; however, the long-term effects were heterogeneous. Our results suggest that reduced amplitude in cVEMP is associated with the effectiveness of ITS injection treatment. •ITS injection is an easy and safe second-line treatment for Meniere's disease.•Satisfactory vertigo control was seen in 18 in 32 patients after the first ITS injection.•Responders showed improvement in low-frequency hearing.•Monthly follow-up is useful to estimate mid- to long-term effects of ITS injection.•Reduced cVEMP amplitude was associated with ITS injection treatment.
ISSN:0196-0709
1532-818X
DOI:10.1016/j.amjoto.2021.103141